DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

When lung cancer advances after initial lines of therapy, the treatment options dwindle. An AbbVie drug gives patients a new choice as the first FDA-approved treatment for advanced cases of non ...

No writing assistance was utilized in the production of this manuscript. Several antibody–drug conjugates (ADCs), using different combinations of antibody, cytotoxic agents and linkers ...

Since its expression is much higher in tumor than normal cells, HER3 is a robust candidate for antibody-drug conjugate (ADC) therapy. Researchers from Heidelberg Pharma AG have presented a new ...

The Trojan horse All three of the studies Verma mentioned involved antibody-drug conjugates (ADCs), a treatment modality that’s now about a decade old but still ripe for innovation.

its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in first-line triple-negative breast cancer (TNBC), Gilead Sciences ...

and TAIPEI, April 21, 2025 /PRNewswire/ -- Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C ...

said Thursday it has signed a deal with an Asia-based biotech company for the production of a clinical-stage antibody-drug conjugate (ADC) candidate. The contract marks the first official step ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...